Erez Aminov - MIRA Pharmaceuticals, CEO Director
| MIRA Stock | 1.27 0.01 0.78% |
CEO
Erez Aminov is CEO Director of MIRA Pharmaceuticals, Common
| Age | 46 |
| Address | 1200 Brickell Avenue, Miami, FL, United States, 32183 |
| Phone | 786-432-9792 |
| Web | https://mirapharmaceuticals.com |
Latest Insider Transactions
Erez Aminov Latest Insider Activity
Tracking and analyzing the buying and selling activities of Erez Aminov against MIRA Pharmaceuticals, stock is an integral part of due diligence when investing in MIRA Pharmaceuticals,. Erez Aminov insider activity provides valuable insight into whether MIRA Pharmaceuticals, is net buyers or sellers over its current business cycle. Note, MIRA Pharmaceuticals, insiders must abide by specific rules, including filing SEC forms every time they buy or sell MIRA Pharmaceuticals,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Erez Aminov over six months ago Acquisition by Erez Aminov of 379000 shares of MIRA Pharmaceuticals at 0.84 subject to Rule 16b-3 | ||
Erez Aminov over six months ago Acquisition by Erez Aminov of 300000 shares of MIRA Pharmaceuticals at 1.15 subject to Rule 16b-3 |
MIRA Pharmaceuticals, Management Efficiency
The company has return on total asset (ROA) of (1.7753) % which means that it has lost $1.7753 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4859) %, meaning that it created substantial loss on money invested by shareholders. MIRA Pharmaceuticals,'s management efficiency ratios could be used to measure how well MIRA Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -2.55. The current year's Return On Capital Employed is expected to grow to -1.85. The current year's Total Current Assets is expected to grow to about 5.1 M, whereas Total Assets are forecasted to decline to about 2.5 M.Similar Executives
| Showing other executives | CEO Age | ||
| Benjamin Filho | ArcelorMittal SA ADR | N/A | |
| Wim Gerven | ArcelorMittal SA ADR | N/A | |
| Victor Cairo | ArcelorMittal SA ADR | N/A | |
| Charles Prober | NETGEAR | 53 | |
| John Brett | ArcelorMittal SA ADR | 59 | |
| Sean Donnelly | ArcelorMittal SA ADR | N/A | |
| Simon Wandke | ArcelorMittal SA ADR | 60 | |
| William McDermott | ServiceNow | 62 | |
| Aditya Mittal | ArcelorMittal SA ADR | 47 | |
| Augustine Kochuparampil | ArcelorMittal SA ADR | 72 | |
| Geert Poelvoorde | ArcelorMittal SA ADR | 55 | |
| Gregory Ludkovsky | ArcelorMittal SA ADR | 74 | |
| Brad Davey | ArcelorMittal SA ADR | 55 | |
| Sanjay Samaddar | ArcelorMittal SA ADR | 59 | |
| Jefferson Paula | ArcelorMittal SA ADR | 62 | |
| Vijay Goyal | ArcelorMittal SA ADR | 51 | |
| David Burritt | United States Steel | 69 | |
| Jose Arias | ArcelorMittal SA ADR | N/A | |
| Hendrik Verster | ArcelorMittal SA ADR | 53 | |
Management Performance
| Return On Equity | -7.49 | ||||
| Return On Asset | -1.78 |
MIRA Pharmaceuticals, Leadership Team
Elected by the shareholders, the MIRA Pharmaceuticals,'s board of directors comprises two types of representatives: MIRA Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MIRA. The board's role is to monitor MIRA Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. MIRA Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MIRA Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD Chapman, Executive Chairman | ||
| Itzchak Angel, Chief Advisor | ||
| Adam MD, President CoFounder | ||
| Michelle MBA, Secretary CFO | ||
| Erez Aminov, CEO Director |
MIRA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MIRA Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.49 | ||||
| Return On Asset | -1.78 | ||||
| Current Valuation | 17.5 M | ||||
| Shares Outstanding | 16.56 M | ||||
| Shares Owned By Insiders | 27.20 % | ||||
| Shares Owned By Institutions | 5.95 % | ||||
| Number Of Shares Shorted | 729.42 K | ||||
| Price To Book | 5.89 X | ||||
| EBITDA | (3.46 M) | ||||
| Net Income | (11.98 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether MIRA Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MIRA Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mira Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mira Pharmaceuticals, Common Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MIRA Pharmaceuticals,. If investors know MIRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MIRA Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (1.78) | Return On Equity (7.49) |
The market value of MIRA Pharmaceuticals, is measured differently than its book value, which is the value of MIRA that is recorded on the company's balance sheet. Investors also form their own opinion of MIRA Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is MIRA Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MIRA Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect MIRA Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MIRA Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if MIRA Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MIRA Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.